The FDA approved a potent new drug therapy for people infected with the liver-destroying hepatitis C. Schering-Plough's product -- Rebetron -- combines ribaviran, an antiviral drug, with interferon, a natural immune-system compound. Rebetron won't cure the deadly illness, but it has dramatically reduced virus levels in 45 percent of patients who have taken the treatment.
Hepatitis Treatment
The FDA approved a potent new drug therapy for people infected with the liver-destroying hepatitis C. Schering-Plough's product -- Rebetron -- combines ribaviran, an antiviral drug, with interferon, a natural immune-system compound. Rebetron won't cure the deadly illness, but it has dramatically reduced virus levels in 45 percent of patients who have taken the treatment.
